CRX Cyprotex

TIDMCRX

RNS Number : 7630E

Cyprotex PLC

20 July 2016

Cyprotex PLC

("Cyprotex" or "the Company")

Trading Update

and Notice of Interim Results

Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first half of 2016.

The financial performance of the Company for the first half of the year is significantly ahead of the Boards expectations, comparative period performance and internal budgets.

The Board expects to announce the Interim Results of the Company on 2 August 2016.

The Board also confirms that the Company's strategic review is progressing.

This announcement contains inside information.

For further information:

 
 Cyprotex PLC                         Tel: +44 (0) 1625 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   ir@cyprotex.com 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad and broker to      Tel: +44 (0)20 7496 
  Cyprotex)                            3000 
 Shaun Dobson                         shaun.dobson@n1singer.com 
  Jen Boorer                           jennifer.boorer@n1singer.com 
                                       www.n1singer.com 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1400 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

TSTBBGDRGSDBGLG

(END) Dow Jones Newswires

July 20, 2016 07:41 ET (11:41 GMT)

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024